Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Institut Bergonie
Sponsor

Institut Bergonie

France 229 Cours De L Argonne, 33000 Bordeaux, France

About the sponsor

Clinical research at Institut Bergonie is strongly centered on soft-tissue sarcoma, including leiomyosarcoma, undifferentiated pleomorphic sarcoma, and resectable or advanced disease. The portfolio also includes osteosarcoma and Ewing sarcoma, with interest in both localized and metastatic settings.

  • Advanced soft-tissue sarcoma
  • Leiomyosarcoma
  • Undifferentiated pleomorphic sarcoma
  • Osteosarcoma and Ewing sarcoma

Research activity spans neoadjuvant, peri-operative, and metastatic sarcoma care, with attention to surgical disease, recurrence risk, and progression control.

About Specializations

Institut Bergonie runs clinical trials in conditions such as Soft tissue sarcoma, Neoplasm, Malignant fibrous histiocytoma, Neoplasm malignant, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Soft tissue sarcoma

Recruiting

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Patients with Resectable Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Institut Bergonie

Malignant fibrous histiocytoma+3

Recruiting

Study of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Bergonie

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Neoplasm

Not recruiting

Study on Atezolizumab and Resiquimod Sulfate with Radiotherapy for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Bergonie

Malignant fibrous histiocytoma+1

Not recruiting

Study on Retifanlimab, Doxorubicin, and Ifosfamide for Adults with Certain Types of Sarcoma in the Abdomen, Limbs, and Trunk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ifosfamide
  • Sponsor:Institut Bergonie

Soft tissue sarcoma

Not recruiting

Study of Nivolumab and Relatlimab for Adults with Advanced or Metastatic Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Institut Bergonie

Neoplasm

Not recruiting

Study on the Effects of Durvalumab and Tazemetostat for Adults with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut Bergonie

Neoplasm

Not recruiting

Study of Regorafenib and Avelumab for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Institut Bergonie

Soft tissue sarcoma

Not recruiting

Study on Berzosertib and Gemcitabine for Adults with Advanced or Metastatic Soft-Tissue Leiomyosarcomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Berzosertib
  • Sponsor:Institut Bergonie

Neoplasm malignant

Not recruiting

Study on the Effects of Ezabenlimab and BI 907828 in Adult Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ezabenlimab
  • Sponsor:Institut Bergonie

Non-small cell lung cancer

Not recruiting

Study on the Effects of Pembrolizumab, Atezolizumab, and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Bergonie

Neoplasm malignant

Not recruiting

Study of Volrustomig for Patients with Advanced Solid Tumors with Mature Tertiary Lymphoid Structures

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Volrustomig
  • Sponsor:Institut Bergonie

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.